Study of Medication Patch to Treat Children Ages 6-12 With ADHD

Massachusetts General Hospital36 enrolled

Overview

The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch. We want to find out how well it treats ADHD during the early morning hours before a child leaves for school or summertime routines.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

ADHD Attention Deficit Hyperactivity Disorder

Interventions

Methylphenidate Transdermal SystemDRUG

Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)

PlaceboDRUG

Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)

Eligibility

Sex: ALLMin age: 6 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female outpatients 6 to 12 years of age. * Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview. * Participation in structured morning routine (e.g. school, camp, or other organized activities). Exclusion Criteria: * Mental retardation (IQ \<75). * Subjects with a medical condition, or treatment that will either jeopardize subject safety or affect the scientific merit of the study. * Subjects with moderate to severe dermatological atopy. * Subjects with known structural cardiac abnormalities. * Organic brain disorders. * Seizure Disorder. * Subjects with Tourette's syndrome, or a history of psychosis or bipolar disorder. * Subjects with current comorbid psychopathology that in the investigator's opinion will warrant immediate treatment or will interfere with the safe execution of the protocol (i.e. Anxiety or Major Depressive Disorder rated as moderate on CGI). * Subjects with a history of intolerable adverse effects or non-response to methylphenidate. * Pregnant or nursing females.

Locations (1)

Massachusetts General Hospital

Cambridge, Massachusetts, United States

Outcomes

Primary Outcomes

Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, Over the Course of the Day.

Units on a scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. The possible range of scores for the scale is 0 (least severe) to 54 (most severe).

Time frame: Baseline and 4 weeks

Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, During the AM.

Time frame: Baseline and 4 weeks

Secondary Outcomes

Efficacy Defined as Change From Baseline on Investigator and Parental/Self-report Based Rating Scales and Questionnaires

The questionnaire includes two a sections, a clinician rated 20-item scale and a 14-item self-report section completed collaboratively by child and parent/guardian. Units on the clinician rated scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. Units on the self-report section ranged from 0-2 on a scale of severity, with 0 being the least severe item score and 2 being the most severe. The possible range of scores for the questionnaire is 88

Time frame: Baseline and 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.